Chemical Compounds
Ponatinib
100%
Tyrosine
94%
Nilotinib
90%
Metabolic
83%
Tumorigenic
77%
Imatinib
76%
Apoptosis Induction
75%
Oncogenic
72%
Tyrosine Kinase Inhibitor
71%
Phosphoinositide
70%
Nutrient
54%
Protein
42%
Medicine & Life Sciences
Protein-Tyrosine Kinases
93%
Phosphotransferases
79%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
65%
Physiological Stress
49%
Endoplasmic Reticulum
39%
Protein Kinases
38%
ponatinib
34%
Activating Transcription Factor 4
31%
Eukaryotic Initiation Factor-2
31%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
29%
Dasatinib
28%
Pharmacology
27%
Proteostasis
26%
K562 Cells
24%
Imatinib Mesylate
23%
TOR Serine-Threonine Kinases
22%
Myeloid Cells
21%
Phosphatidylinositol 3-Kinase
20%
Nutrients
17%
Apoptosis
12%
Neoplasms
6%